Menu
Not yet recruiting NCT06937268

DOTATATE PET for Meningioma Radiation Planning

No phase Interventional Meningioma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: DOTATATE-PET scan.
Who it may be relevant to
Registry conditions: Meningioma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning

Overview

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Interventions

  • Diagnostic test DOTATATE-PET scan
    DOTATATE tracer PET scan for meningioma

Primary outcome measures

  • Target radiation volume [Time frame: 2 years]
Secondary outcome measures (7)
  • Local control [Time frame: 2 years]
  • Progression-free survival [Time frame: 2 years]
  • Perceived usefulness by radiation oncologist [Time frame: 2 years]
  • Adverse event [Time frame: 2 years]
  • Rate of DOTATATE-scan completion [Time frame: 2 years]
  • Extent of post-operative disease volume compared to MRI [Time frame: 2 years]
  • Overall survival [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years old
  • Able and willing to comply with the study procedures
  • Intact meningioma requiring definitive radiation
  • Post-operative meningioma requiring adjuvant radiation
  • No prior radiation therapy or medical therapy directed at the tumour

Exclusion criteria

  • Breastfeeding or pregnancy
  • Claustrophobia or inability to lie still in a supine position
  • Unwillingness or inability to provide informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Canada · 1 center
  • BC Cancer - Vancouver — Vancouver

Identifiers

NCT: NCT06937268 · H22-03733

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗